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There is increasing evidence that elevated concentrations of interleukin-2 (IL-2) and its soluble receptor may reflect the clinical course of multiple sclerosis (MS). -' T lymphocytes expressing IL-2 or IL-2 receptor have been detected in demyelinated plaques in brains obtained at necropsy of patients with active MS.6'8 Clinical studies have also reported increased concentrations of IL-2 in serum or CSF of patients with clinically active MS,9-"1 and serum or CSF levels of soluble IL-2 receptor (sIL-2R) were shown to be significantly higher in patients with active MS compared with patients in remission.' 1o 12 Moreover, Hartung et al '3 reported that serum concentrations of sIL-2R apparently paralleled MS disease activity although these concentrations did not correlate with the clinical score by which disease severity was assessed.
For the clinician, assessment of disease activity in MS patients is important not only from a prognostic view point, but also to monitor the efficacy of therapeutic interventions. Although MRI can visualise lesion dissemination, assessment of disease activity in MS is essentially clinical,'4 relying on evidence of a relapse or increasing disability. These clinical measures, however, do not suffice because of intrinsic variability of the disease and subjective differences between clinical observers. 5 We therefore elected to determine whether intrathecal levels of IL-2 and sIL-2R in MS correlate with clinical disease activity. We measured concentrations of IL-2 and sIL-2R in serum and CSF samples from MS patients in relapse and remission, and compared the results with levels of IgG index '6 which estimates the intrathecal humoral immune response.
Patients and methods Patients
We obtained paired serum and CSF samples from 63 patients (39 women and 24 men; median age, 27-2 years; age range, 20-5 to 50 years) with clinically definite MS.17 The median duration of the illness was 5-2 years (range, 1 2 to 14-5 years). All had relapsingremitting disease with high prestudy relapse rates (at least 0-7 per years) and 42 patients were in clinical relapse during CSF collection. We defined the relapse phase as within 2 weeks of worsening of existing symptoms(s) provided that the course has been stationary or has improved during the previous month. 8 Remission was defined as improvement in symptoms or signs for at least one month. '7 No patient involved in the study has received immunosuppressive treatment for at least 8 months from the CSF collection. The degree of disability at the time of CSF collection was assessed with the expanded disability status scale (EDSS).'9 The date of onset of MS and the number of relapses per year were obtained from previous medical records Controls Twenty six patients with non-inflammatory nervous diseases were included in the study to serve as neurological controls. Their diagnoses included Alzheimer's disease (5 patients), motor neuron disease (6 patients), benign intracranial hypertension (4 patients), cerebrovascular diseases (7 patients), and epilepsy (4 patients). Paired samples were also obtained from 14 (fig 2) , whereas no significant difference was detected between serum levels of sIL-2R in MS relapse and remission (p = 0 07).
Intrathecal cytokine release in clinically active MS We standardised levels of IL-2 and sIL-2R CSF and serum of MS patients in relapse by calculating their ratios to albumin concentrations, as previously described,4 1 20 to correct for passive transudation through blood-CSF barriers. Standardised CSF concentrations of IL-2 (95% CI of 2 3 to 10 1 U/mg of albumin) were significantly higher than corresponding serum levels (95% CI of 0d17 to 0 73 U/mg of albumin), suggesting local release of IL-2 within the intrathecal compartment.20 Similarly, standardised sIL-2R levels in CSF (95% CI of 139 to 243 U/mg of albumin) were significantly higher than serum levels (95% CI of 1-4 to 5-4 U/mg of albumin), indicating intrathecal release of sIL-2R in clinically active MS. Calculation of cytokine index values"6 also detected intrathecal release of IL-2 and sIL-2R in patients with active MS (data not shown).
Cytokine levels and clinical features of MS CSF concentrations of IL-2 and sIL-2R correlated with the degree of disability, as manifested by EDSS, in patients with clinically active disease (table 1). In contrast, serum levels of IL-2 or sIL-2R in these patients failed to correlate with the EDSS score. Similarly, CSF levels of IL-2 and sIL-2R in remission did not correlate with degree of disability. IgG index in patients with clinically active MS correlated with the EDSS score (table 1) .
In addition to their correlation with the degree of disability, CSF concentrations of IL-2 and sIL-2R in clinically active disease showed good correlation with the total number of relapses per year, and correlated inversely with total disease duration. Interestingly, serum concentrations of IL-2 and sIL-2R in clinically active MS also correlated with total disease duration (r = 0-36 and 0X32 respectively), whereas IgG index values failed to correlate with total disease duration or the number of relapses per year (table 1).
Discussion
In this study, we detected higher CSF concentrations of IL-2 and sIL-2R in patients with : . 33 The mechanism by which intrathecal release of IL-2 and sIL-2R relates to the degree of 
